Drug intelligence / Profile preview

DCB-101

Development stage: Preclinical
Lead developer: Dewcell Biotherapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Oral

Overview

DCB-101 is a preclinical-stage stem cell therapy developed by DewCell Biotherapeutics. It is being investigated for the treatment of ischemia, a condition characterized by insufficient blood supply to an organ or tissue, within the broader therapeutic area of cardiovascular diseases. While the precise mechanism of action for ischemia is not detailed, DewCell Biotherapeutics focuses on developing stem cell-based therapies, including those for producing transfusion-grade platelets.

Beyond the preview

Go deeper on DCB-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DCB-101.

Explore the full profile